Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5237998 | 0.86 | HTR2A (0.56) | TSHRGAASMN1; SMN2MEN1KMT2A | |
| SCHEMBL5241628 | 0.83 | PTGS2 (0.50) | GAAHSD17B10MEN1KMT2AHTR2A | |
| SCHEMBL5238133 | 0.78 | TSHR (0.59) | TSHRGAASMN1; SMN2HSD17B10LMNA | |
| SCHEMBL10196371 | 0.78 | TSHR (0.53) | TSHRGAASMN1; SMN2HSD17B10LMNA | |
| SCHEMBL6775456 | 0.77 | TSHR (0.48) | TSHRGAASMN1; SMN2HSD17B10LMNA | |
| SCHEMBL6001524 | 0.77 | LTA4H (0.43) | TSHRGAASMN1; SMN2HSD17B10LMNA | |
| SCHEMBL9541800 | 0.76 | TSHR (0.57) | TSHRGAASMN1; SMN2HSD17B10LMNA | |
| SCHEMBL5234818 | 0.76 | TSHR (0.52) | TSHRGAASMN1; SMN2HSD17B10LMNA | |
| SCHEMBL5254326 | 0.76 | CYP1A2 (0.41) | TSHRSMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL11526354 | 0.76 | TUBB1 (0.47) | TSHRGAASMN1; SMN2HSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5922759-A | Butenolide endothelin antagonists | WARNER-LAMBERT COMPANY (US) | 1999-07-13 | — | — | US | claimed |
| US-5691373-A | TREATING SUBARACHNOID HEMORRHAGE | WARNER-LAMBERT COMPANY (US) | 1997-11-25 | — | — | US | claimed |
| WO-1997002265-A1 | BUTENOLIDE ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1997-01-23 | — | — | WO | claimed |
| CN-1266151-C | Naphthyridine derivatives | OTSUKA PHARMA CO LTD (JP) | 2006-07-26 | — | — | CN | disclosed |
| US-7071187-B2 | Naphthyridine derivatives | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2006-07-04 | — | — | US | disclosed |
| CN-1547581-A | Naphthyridine derivatives | 株式会社大V制药工场 | 2004-11-17 | — | — | CN | disclosed |
| US-20040214853-A1 | Naphthyridine derivatives | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2004-10-28 | — | — | US | disclosed |
| EP-1426374-A1 | NAPHTHYRIDINE DERIVATIVE | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2004-06-09 | — | — | EP | disclosed |
| EP-0638075-B1 | THIAZOLE OR IMIDAZOLE DERIVATIVES AS MAILLARD REACTION INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2002-01-16 | — | — | EP | disclosed |
| US-6017951-A | TREATING RENAL FAILURE, HYPERTENSION, MYOCARDIAL INFARCTION AND MYOCARDIAL ISCHEMIA, CEREBRAL VASOSPASM, CIRRHOSIS, SEPTIC SHOCK, CONGESTIVE HEART FAILURE, ENDOTOXIC SHOCK, SUBARACHNOID HEMORRHAGE, ARRHYTHMIAS, ASTHMA, ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 2000-01-25 | — | — | US | disclosed |
| US-5922759-A | Butenolide endothelin antagonists | WARNER-LAMBERT COMPANY (US) | 1999-07-13 | — | — | US | disclosed |
| US-5677322-A | THERAPY FOR AGING, DIABETES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-10-14 | — | — | US | disclosed |
| WO-1997002265-A1 | BUTENOLIDE ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1997-01-23 | — | — | WO | disclosed |
| EP-0638075-A1 | THIAZOLE OR IMIDAZOLE DERIVATIVES AS MAILLARD REACTION INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-02-15 | — | — | EP | disclosed |
| WO-1994019335-A1 | THIAZOLE OR IMIDAZOLE DERIVATIVES AS MAILLARD REACTION INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214853-A1 | Naphthyridine derivatives | MT-ND1, OPRD1, NR0B1 | TSHR 2365/4885GAA 1753/4885SMN1; SMN2 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.